Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.
Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.
Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.
Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS' clinical trial for MDMA-assisted psychotherapy.
Mydecine signs an LOI to provide The Newly Institute with psilocybin and MDMA for use in Health Canada SAP-approved psychedelics-based therapy.
Optimi Health submits a patent application for the extraction process for its natural psilocybin extract.
Better Life Pharma reports encouraging pre-clinical results for its non-hallucinogenic psychedelic analog.
Novamind to host a Phase I clinical trial of a ketamine-assisted therapy for Opioid Use Disorder.
Mydecine seeks to become a psilocybin supplier for new applications for psilocybin-therapy under Canada's SAP.
atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.
Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it's lead drug candidate for Traumatic Brain Injury.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now